{"id":14355,"date":"2019-10-25T09:15:27","date_gmt":"2019-10-25T13:15:27","guid":{"rendered":"https:\/\/medicarereport.org\/?p=14355"},"modified":"2019-10-25T09:15:27","modified_gmt":"2019-10-25T13:15:27","slug":"pharma-sells-states-on-netflix-model-to-wipe-out-hep-c-but-at-what-price","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=14355","title":{"rendered":"Pharma Sells States On \u2018Netflix Model\u2019 To Wipe Out Hep C. But At What Price?"},"content":{"rendered":"

(By JoNel Aleccia, Barbara Feder Ostrov, and Donna Gordon Blankinship for Kaiser Health News)<\/p>\n

When a long, black bus bearing the logo of drugmaker AbbVie rolls through Washington state next year, it will promote a new effort to eradicate hepatitis C infections.<\/p>\n

The state is paying for the marketing campaign as part of a deal to give AbbVie the exclusive right to treat its citizens who have the potentially deadly liver disease. Armed with its medication, Mavyret, AbbVie beat out rivals Merck and Gilead Sciences in a blind bidding process.<\/p>\n

It\u2019s the second time this year that a state has struck a novel deal with a pharmaceutical company to obtain drugs that can cure hepatitis C \u2015 with discounts from a price that came to market at $84,000 for a course of treatment.\u00a0 Continue reading article here…<\/a><\/p>\n

Kaiser Health News is a nonprofit national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation<\/p>\n

\"\"<\/a><\/p>\n

Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"
(By JoNel Aleccia, Barbara Feder Ostrov, and Donna Gordon Blankinship for Kaiser Health News) When a long, black bus bearing<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21,20,16,15],"tags":[],"class_list":["post-14355","post","type-post","status-publish","format-standard","hentry","category-health-care-finance","category-health-care-redesign","category-medicaid","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14355"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14355\/revisions"}],"predecessor-version":[{"id":14356,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14355\/revisions\/14356"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}